Evidence map›Paper›PMID 30355436›Full record

ArticleBMB reports2019

CCAAT/enhancer-binding protein beta (C/EBPβ) is an important mediator of 1,25 dihydroxyvitamin D3 (1,25D3)-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in osteoblasts.

Sungsin Jo, Yun Young Lee, Jinil Han, Young Lim Lee, Subin Yoon, Jaehyun Lee, Younseo Oh, Joong-Soo Han, Il-Hoon Sung, Ye-Soo Park and 1 more

Open access · goldAbstract read
PubMed Full text at PMC
In one paragraph

Article in BMB reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sungsin JoHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea.
Yun Young LeeDepartment of Biomedical Sciences, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Jinil HanGencurix, Inc, Seoul 08394, Korea.
Young Lim LeeHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea.
Subin YoonHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea; Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Jaehyun LeeHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea; Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Younseo OhHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea; Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Joong-Soo HanHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea; Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Il-Hoon SungDepartment of Orthopedic Surgery, Hanyang University Hospital, Seoul 04763, Korea.
Ye-Soo ParkDepartment of Orthopedic Surgery, Hanyang University Hospital, Seoul 04763, Korea.
Tae-Hwan KimHanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea.
Hanyang University Seoul Hospital · KRHanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteoblasts is regulated by 1,25-dihydroxyvitamin D3 (1,25D3). CCAAT/enhancer-binding protein beta (C/EBPβ) has been proposed to function as a transcription factor and upregulate RANKL expression, but it is still uncertain how C/EBPβ is involved in 1,25D3-induced RANKL expression of osteoblasts. 1,25D3 stimulation increased the expression of RANKL and C/EPBβ genes in osteoblasts and enhanced phosphorylation and stability of these proteins. Moreover, induction of RANKL expression by 1,25D3 in osteoblasts was downregulated upon knockdown of C/EBPβ. In contrast, C/EBPβ overexpression directly upregulated RANKL promoter activity and exhibited a synergistic effect on 1,25D3-induced RANKL expression. In particular, 1,25D3 treatment of osteoblasts increased C/EBPβ protein binding to the RANKL promoter. In conclusion, C/EBPβ is required for induction of RANKL by 1,25D3. [BMB Reports 2019; 52(6): 391-396].

Indexed as

Binding SitesCalcitriolCCAAT-Enhancer-Binding Protein-betaCell DifferentiationCell LineCell NucleusHumansNF-kappa BOsteoblastsPhosphorylationPromoter Regions, GeneticProtein BindingProtein StabilityRANK LigandRNA, MessengerCalcitriolCCAAT-Enhancer-Binding Protein-betaNF-kappa BRANK LigandRNA, MessengerTNFSF11 protein, human

Identifiers

PMID30355436
PMCPMC6605518
OpenAlexW2954915367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.